Researchers track safety of Bone-Strengthening drug in kids years after treatment
NCT ID NCT07366086
Summary
This study aims to monitor the long-term safety of a drug called romosozumab in children and adolescents with osteogenesis imperfecta (brittle bone disease). It follows 71 young people who completed a previous treatment trial to check for any delayed side effects. The main goal is to see how safe the treatment was over a longer period after they stopped taking the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.